Actively Recruiting
Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
Led by Sohag University · Updated on 2025-06-12
120
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem autoimmune disease characterized by pathogenic autoantibodies production against nuclear structures . SLE affecting mainly women of childbearing age and is characterized by unpredictable flares and remissions. Disease severity varied from a mild episodic disorder to a rapidly progressive life-threatening illness. The kidney is the most commonly involved visceral organ in SLE. Therefore, identifying new noninvasive biomarkers of LN severity and outcome is mandatory. IL-17 is a potent pro-infammatory cytokine that amplifes T-cell activation and stimulates fibroblast cells, endothelial, and epithelial cells to produce several pro-infammatory mediators, including IL-1β, IL-6, and TNF-α. IL-17 receptor signaling enhances the expression of multiple pro-infammatory mediators. Hence, IL-17 enhances the production of neutrophil-attracting chemokines
CONDITIONS
Official Title
Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Diagnosed with systemic lupus erythematosus (SLE) meeting SLICC classification criteria
- Able to cooperate and answer questions
- Willing and able to provide written informed consent
You will not qualify if you...
- Having other autoimmune diseases
- Receiving any hyperuricemia treatment
- Pregnant
- Having malignancy
- Diagnosed with diabetes
- Diagnosed with hypertension
- Having heart failure
- Having hepatic diseases
- Having chronic renal failure not caused by lupus nephritis
- Having renal artery stenosis
- Having renal vein thrombosis
- Having intrarenal arteriovenous fistula
- Having obstructive nephropathy
- Having urinary tract obstruction affecting intra renal artery resistance index
- Uncooperative patients
- Unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sohag university Hospital
Sohag, Egypt
Actively Recruiting
Research Team
S
Sara M Ahmed, resident
CONTACT
A
abdelhady R Abdel-Gawad, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here